•
Dec 31, 2024

Inozyme Q4 2024 Earnings Report

Inozyme reported a widened net loss in Q4 2024 while prioritizing its ENPP1 Deficiency program and implementing cost-saving measures.

Key Takeaways

Inozyme's Q4 2024 results reflect its strategic prioritization of the ENPP1 Deficiency program, including a 25% workforce reduction to extend its cash runway into 2026. The company reported a net loss of $102.0 million for the year, with no revenue recorded. Cash and cash equivalents stood at $113.1 million as of December 31, 2024, providing operational stability despite increased R&D expenses. Enrollment for the pivotal ENERGY 3 trial was completed, with topline data expected in Q1 2026.

No revenue recorded for Q4 2024 as the company remains in clinical development.

Net loss increased to $102.0 million for the year, with EPS at -$1.62.

Cash, cash equivalents, and investments totaled $113.1 million as of December 31, 2024.

ENERGY 3 pivotal trial enrollment completed, with topline data expected in Q1 2026.

Total Revenue
$0
Previous year: $1.98M
-100.0%
EPS
-$0.42
Previous year: -$0.33
+27.3%
Weighted Average Shares
62.81M
Previous year: 51.84M
+21.2%
Gross Profit
-$283K
Previous year: $1.67M
-116.9%
Cash and Equivalents
$113M
Previous year: $189M
-40.0%
Free Cash Flow
-$19.2M
Previous year: -$18.6M
+3.3%
Total Assets
$123M
Previous year: $201M
-38.7%

Inozyme

Inozyme

Forward Guidance

Inozyme expects to continue focusing on its ENPP1 Deficiency program, aiming for a Biologics License Application (BLA) submission and topline data from the pivotal trial in 2026.

Positive Outlook

  • Company’s cash reserves expected to support operations into Q1 2026.
  • ENERGY 3 pivotal trial for ENPP1 Deficiency fully enrolled.
  • Strategic prioritization to focus on core programs and reduce costs.
  • Potential for Biologics License Application (BLA) submission in 2026.
  • Positive interim results from the ENERGY 1 trial in infants.

Challenges Ahead

  • No revenue expected until product approval and commercialization.
  • Net losses expected to continue due to high R&D expenses.
  • Workforce reduction may impact operational efficiency.
  • Future trials in ABCC6 Deficiency and calciphylaxis postponed.
  • Regulatory approval risks remain for the ENPP1 Deficiency program.